Piramal Pharma Limited has announced a net profit of ₹196.33 crore for the second quarter of FY2025, marking a significant increase from the previous quarter’s profit of ₹113.14 crore. This financial performance was disclosed during the company's board meeting held on 5th November 2025. The company also reported a total revenue from operations of ₹1,127.26 crore, which shows a notable increase from ₹969.88 crore in the previous quarter. However, when compared to the same quarter last year, the revenue reflects a decline from ₹1,284.39 crore.

The company's expenses for the quarter amounted to ₹1,081.82 crore, slightly higher than the ₹1,008.22 crore reported in the previous quarter, with significant costs attributed to materials consumed and other operational expenses. The profit before tax reached ₹247.41 crore, indicating a solid operational performance despite the rising costs. Alongside these results, the Board of Directors approved the unaudited financial results for the half-year ended on 30th September 2025, showcasing a year-to-date income of ₹2,480.03 crore against ₹2,490.73 crore from the previous year.

Piramal Pharma's earnings per share (EPS) for the quarter stood at ₹1.48, reflecting a consistent performance amid fluctuating market conditions. The total comprehensive income for the period was reported at ₹168.90 crore, slightly down from ₹208.96 crore in the corresponding quarter of the previous year. The company aims to publish its financial results in newspapers in compliance with the SEBI Listing Regulations and has made the information available on its official website. With a paid-up equity share capital of ₹1,325.52 crore, Piramal Pharma continues to strengthen its market position despite various challenges.